Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adrulipase alfa - First Wave BioPharma/Mayoly-Spindler

Next Previous
Drug Profile

Adrulipase alfa - First Wave BioPharma/Mayoly-Spindler

Alternative Names: Adrulipase; MS-1819; MS1819-SD; Recombinant lipase - First Wave BioPharma/Mayoly-Spindler

Latest Information Update: 05 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mayoly-Spindler
  • Developer First Wave BioPharma; Mayoly-Spindler
  • Class Anti-inflammatories; Carboxylic ester hydrolases; Pancreatic enzymes; Recombinant proteins
  • Mechanism of Action Lipase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Exocrine pancreatic insufficiency; Pancreatitis

Most Recent Events

  • 05 Apr 2024 First Wave Biopharma announced intention to schedule a Type C meeting with the FDA in the first half of 2024 (First Wave BioPharma SEC 2024)
  • 31 Dec 2023 First Wave Biopharma has patents pending for Adrulipase formulations in USA (First Wave BioPharma SEC 2024)
  • 13 Jul 2023 First Wave Biopharma plans to conduct the end-of-phase II meeting with the US FDA in the fourth quarter of 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top